TITAN PHARMACEUTICALS INC — Director's Dealing 2018

Oct 22, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TITAN PHARMACEUTICALS INC (TTNP)
CIK: 0000910267
Period of Report: 2018-10-19

Reporting Person: Recli Federico Seghi (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-19	Common Stock	P	200000	—	Acquired	800845	Direct

Footnotes

F1: The weighted average price is $0.4084 per share while the low trade price is at $0.399 and the high trade price at $0.41.